Changes in Posterior Ocular Structures in Individuals Using Phosphodiesterase 5 Inhibitor

References

• Kerr NM, Danesh-Meyer HV. Phosphodiesterase inhibitors and the eye. Clin Exp Ophthalmol. 2009;37(5):514–523. doi: 10.1111/j.1442-9071.2009.02070.x.
   PubMed Web of Science ®Google Scholar
• Laties A, Zrenner E. Viagra (sildenafl citrate) and ophthalmology. Prog Retin Eye Res. 2002;21(5):485–506. doi: 10.1016/s1350-9462(02)00013-7.
   PubMed Web of Science ®Google Scholar
• Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–2157. doi: 10.1056/NEJMoa050010.
   PubMed Web of Science ®Google Scholar
• Ravipati G, McClung JA, Aronow WS, Peterson SJ, Frishman WH. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. Cardiol Rev. 2007;15(2):76–86. doi: 10.1097/01.crd.0000233904.77128.49.
   PubMedGoogle Scholar
• Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998;338(20):1397–1404. doi: 10.1056/NEJM199805143382001.
   PubMed Web of Science ®Google Scholar
• Danesh-Meyer HV, Levin LA. Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association? Br J Ophthalmol. 2007;91(11):1551–1555. doi: 10.1136/bjo.2007.125880.
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov. 2006;5(8):689–702. doi: 10.1038/nrd2030.
   PubMed Web of Science ®Google Scholar
• Fraunfelder FW. Visual side effects associated with erectile dysfunction agents. Am J Ophthalmol. 2005;140(4):723–724. doi: 10.1016/j.ajo.2005.02.049.
   PubMed Web of Science ®Google Scholar
• Zurawin JL, Stewart CA, Anaissie JE, Yafi FA, Hellstrom WJ. Avanafil for the treatment of erectile dysfunction. Expert Rev Clin Pharmacol. 2016;9(9):1163–1170. doi: 10.1080/17512433.2016.1212655.
   PubMed Web of Science ®Google Scholar
• Gong B, Ma M, Xie W, Yang X, Huang Y, Sun T, Luo Y, Huang J. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int Urol Nephrol. 2017;49(10):1731–1740. doi: 10.1007/s11255-017-1644-5.
   PubMed Web of Science ®Google Scholar
• Diederen RM, La Heij EC, Markerink-van Ittersum M, Kijlstra A, Hendrikse F, de Vente J. Selective blockade of phosphodiesterase types 2, 5 and 9 results in cyclic 3'5’ guanosine monophosphate accumulation in retinal pigment epithelium cells. Br J Ophthalmol. 2007;91(3):379–384. doi: 10.1136/bjo.2006.100628.
   PubMed Web of Science ®Google Scholar
• Donahue SP, Taylor RJ. Pupil-sparing third nerve palsy associated with sildenafl citrate (Viagra). Am J Ophthalmol. 1998;126(3):476–477. doi: 10.1016/s0002-9394(98)00243-8.
   PubMed Web of Science ®Google Scholar
• Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168(4 Pt 1):1332–1336. doi: 10.1016/S0022-5347(05)64442-4.
   PubMed Web of Science ®Google Scholar
• Agrawal R, Gupta P, Tan KA, Cheung CM, Wong TY, Cheng CY. Choroidal vascularity index as a measure of vascular status of the choroid: measurements in healthy eyes from a population-based study. Sci Rep. 2016;6(1):21090. doi: 10.1038/srep21090.
   PubMed Web of Science ®Google Scholar
• Etminan M, Sodhi M, Mikelberg FS, Maberley D. Risk of Ocular Adverse Events Associated With Use of Phosphodiesterase 5 Inhibitors in Men in the US. JAMA Ophthalmol. 2022;140(5):480–484. doi: 10.1001/jamaophthalmol.2022.0663.
   PubMed Web of Science ®Google Scholar
• Barroso F, Ribeiro JC, Miranda EP. Phosphodiesterase type 5 inhibitors and visual side effects: a narrative review. J Ophthalmic Vis Res. 2021;16(2):248–259. doi: 10.18502/jovr.v16i2.9088.
   PubMed Web of Science ®Google Scholar
• Azzouni F, Abu Samra K. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. J Sex Med. 2011;8(10):2894–2903. doi: 10.1111/j.1743-6109.2011.02382.x.
   PubMed Web of Science ®Google Scholar
• Bollinger K, Lee MS. Recurrent visual field defect and ischemic optic neuropathy associated with tadalafil rechallenge. Arch Ophthalmol. 2005;123(3):400–401. doi: 10.1001/archopht.123.3.400.
   PubMedGoogle Scholar
• Coscas F, Coscas G, Zucchiatti I, Bandello F, Soubrane G, Souïed E. Optical coherence tomography in tadalafil-associated retinal toxicity. Eur J Ophthalmol. 2012;22(5):853–856. doi: 10.5301/ejo.5000127.
   PubMed Web of Science ®Google Scholar
• Gordon-Bennett P, Rimmer T. Central serous chorioretinopathy following oral tadalafil. Eye. 2012;26(1):168–169. doi: 10.1038/eye.2011.250.
   PubMed Web of Science ®Google Scholar
• Gargallo-Benedicto A, Clemente-Tomás R, Pastor-Espuig M, Alías-Alegre EG, Navarro-Casado MN. Bilateral neurosensory retinal detachment secondary to tadalafil treatment. Arch Soc Esp Oftalmol (Engl Ed). 2022;97(4):234–238. doi: 10.1016/j.oftale.2020.11.015.
   PubMedGoogle Scholar
• Capece M, Montorio D, Comune C, Aveta A, Melchionna A, Celentano G, Imbimbo C, Crocetto F, Califano G, Cennamo G. Retinal and optic disc vascular changes in patients using long-term tadalafil: a prospective non-randomized matched-pair study. Diagnostics (Basel). 2021;11(5):802. doi: 10.3390/diagnostics11050802.
   PubMedGoogle Scholar
• Beck RW, Servais GE, Hayreh SS. Anterior ischemic optic neuropathy. IX. Cup-to-disc ratio and its role in pathogenesis. Ophthalmology. 1987;94(11):1503–1508.
   PubMed Web of Science ®Google Scholar
• Shir Yen W, Yathavan S, Ramli MA, Siu Wan F, Che Hamzah J. Bilateral sequential Non-arteritic Anterior Ischemic Optic Neuropathy (NAION). Cureus. 2021;13(11):e19408. doi: 10.7759/cureus.19408.
   PubMed Web of Science ®Google Scholar
• Liu B, Zhu L, Zhong J, Zeng G, Deng T. The association between phosphodiesterase type 5 inhibitor use and risk of non-arteritic anterior ischemic optic neuropathy: a systematic review and meta-analysis. Sex Med. 2018;6(3):185–192. doi: 10.1016/j.esxm.2018.03.001.
   PubMed Web of Science ®Google Scholar
• Paris G, Sponsel WE, Sandoval SS, Elliott WR, Trigo Y, Sanford DK, Harison JM. Sildenafil increases ocular perfusion. Int Ophthalmol. 2001;23(4-6):355–358. doi: 10.1023/a:1014410932321.
   PubMedGoogle Scholar
• Aslan F, Topcuoğlu M, Öktem Ç, Akkoç A, Uçar M. Can subfoveal choroidal thickness replace subjective tests in patients using tadalafil to treat erectile dysfunction? Andrologia. 2020;52(6):e13580. doi: 10.1111/and.13580.
   PubMed Web of Science ®Google Scholar
• Bill A, Sperber GO. Control of retinal and choroidal blood flow. Eye. 1990;4(2):319–325. doi: 10.1038/eye.1990.43.
   PubMedGoogle Scholar
• Haefliger IO, Flammer J, Lüscher TF. Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery. Invest Ophthalmol Vis Sci. 1992;33(7):2340–2343.
   PubMed Web of Science ®Google Scholar
• Delaey C, Van De Voorde J. Regulatory mechanisms in the retinal and choroidal circulation. Ophthalmic Res. 2000;32(6):249–256. doi: 10.1159/000055622.
   PubMed Web of Science ®Google Scholar
• Xie J, Ye L, Chen Q, Shi Y, Hu G, Yin Y, Zou H, Zhu J, Fan Y, He J, et al. Choroidal thickness and its association with age, axial length, and refractive error in Chinese adults. Invest Ophthalmol Vis Sci. 2022;63(2):34. doi: 10.1167/iovs.63.2.34.
   PubMed Web of Science ®Google Scholar
• Sabaner MC, Dogan M, Akdogan M, Karadag S, Onur IU, Tasci Aİ, Yigit FU. Evaluation of retinal and choroidal microcirculation alterations after a single dose of oral 5-mg tadalafil: a prospective pilot optical coherence tomography angiography study. J Ocul Pharmacol Ther. 2021;37(7):421–429. doi: 10.1089/jop.2020.0124.
   PubMed Web of Science ®Google Scholar